Along with exploratory and GLP toxicology studies, TetraQ offers access to pharmacokinetic (PK) and toxicokinetic (TK) trials. TetraQ’s preclinical node operates with a group of highly trained and dedicated staff expert in the use of standard administration routes including oral, intravenous, intramuscular, subcutaneous, intradermal and intraperitoneal. Our facility contains dedicated areas for dose administration and surgery, with the latter including options for gaseous isoflurane anaesthesia as well as injectable anaesthestics.
Past clients for our services include Australian universities and non-profit organisations as well as Australian and overseas biotechs. Australian subsidiaries of international companies can in many cases access benefits from the Federal Government’s Research and Development Tax Incentive for studies run at TetraQ.
To support PK studies, TetraQ offers surgical implantation of rats with intravenous and intraarterial cannulas. This permits integration with a state-of-the-art BASi Culex system for drug dosing and blood collection from multiple animals at custom times. The BASi Culex system was developed for collection of pharmacokinetic and pharmacodynamic data from rats, mice, and other small rodents. It automatically collects blood, urine and fecal samples from awake and freely-moving animals, thereby reducing animal stress, improving technician productivity and increasing throughput.
Samples collected in pharmacokinetics/toxicokinetics studies can be analysed at TetraQ’s bioanalytical facility at a research-only or GLP level. Method development and full or partial validation is available for both small molecules and proteins in matrices including plasma, serum, urine or tissue homogenates. Protein biomarker analysis can also be run at TetraQ using commercial ELISA kits or Meso Scale Discovery (MSD) multiplexed kits. However, on sponsor request we can also ship samples to an external facility for analysis.